AJJ Medtech Holdings Limited: FY2025 Financial Review and Investor Analysis

AJJ Medtech Holdings Limited, listed on the Catalist Board of SGX-ST, released its unaudited condensed interim financial statements for the quarter and year ended 31 December 2025. The company operates in the medtech space, focusing on investment holding and integrated healthcare solutions.

Key Financial Metrics and Comparative Table

Historical Performance Trends

• Revenue for FY2025 increased by 37.4% YoY to S\$3.19 million, driven by stronger performance in its Healthcare Products and Services segment and franchise fee income from the Holding company.
• Gross profit doubled YoY to S\$1.17 million, with improved margins due to franchise fee income and higher sales of high-margin consumables.
• Net loss narrowed to S\$2.93 million for FY2025, from S\$3.87 million in FY2024, reflecting successful cost management and increased sales.
• Net asset value per share dropped to (0.1585)c from (0.0973)c, indicating continued asset erosion despite equity fundraising.

Cash Flow and Capital Structure

• Operating cash outflow was S\$0.77 million for FY2025, reflecting ongoing losses but improved working capital management.
• Net cash generated from financing activities (S\$1.25 million) was driven by share placements, director advances, and factoring facilities.
• Share capital increased following the issuance of 127.5 million new ordinary shares via private placement and 81.1 million shares through employee share awards.
• Debt and related-party liabilities remain significant, with S\$3.26 million owed to directors and related parties, accounting for 52% of total liabilities at the group level.

Exceptional Earnings and Expenses

• Performance share awards expenses accounted for S\$0.81 million in 4Q2025 and S\$0.81 million in FY2025, impacting net results.
• No material related-party transactions were disclosed apart from director and related-party loans.
• No asset revaluations, divestments, IPOs, or major asset sales were reported.

Dividend Policy

• No dividends declared or recommended for FY2025 or FY2024, as the Group remains loss-making and is focusing on business expansion.

Corporate Actions

• Substantial dilution occurred: total issued shares increased from 1.50 billion to 1.71 billion in 2025. No treasury shares or subsidiary holdings at year-end.
• No share buybacks or general mandate for interested person transactions was obtained.

Events Affecting Business and Outlook

• Key strategic milestones include partnerships for elderly care robotics and long-term supply contracts with public healthcare networks.
• Performance in the next year depends on the execution of secured contracts and regulatory approvals for new ventures.
• No legal disputes, natural disasters, or policy changes affecting the company were disclosed.

Chairman’s Statement

“The healthcare sector continues to face significant cost pressures and demands for operational resilience, defining the competitive conditions in which we operate. Our strategy to navigate this environment involves supply chain diversification and disciplined inventory management. Our core medical device division provides stability, while strategic initiatives such as our smart elderly care robotics joint venture represent targeted investments for future growth.”

Tone: Cautiously optimistic, emphasizing operational discipline and future-focused investment, but acknowledging industry challenges and cost pressures.

Conclusion and Recommendation

Overall, AJJ Medtech Holdings Limited demonstrated improved revenue, gross profit, and narrowed losses in FY2025, reflecting progress in operational efficiency and revenue growth. However, the company remains loss-making, highly leveraged with director/related-party debt, and continues to dilute shareholders through equity fundraising. The lack of dividend and negative net asset value per share highlight ongoing challenges.

Recommendation for current holders: Investors currently holding AJJ Medtech should monitor contract execution and regulatory progress closely. Given the improved financial trajectory but ongoing losses and dilution, consider holding if you anticipate further operational turnaround and revenue growth from new contracts. However, risk remains elevated.

Recommendation for prospective investors: Those not currently holding the stock should exercise caution. Wait for signs of sustained profitability, further reduction in leverage, and evidence of successful contract execution before considering entry. The risk profile remains high, and dilution risk persists.

Disclaimer: This analysis is based strictly on information disclosed in the official financial report. It does not constitute investment advice. Please conduct your own research or consult a professional advisor before making any investment decision.

View AJJ Medtech Historical chart here